Skip to Main Content

Paper Details

Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data.
mBio
8
2023
COVID-19, COVID-19 infection, Omicron, Patients, SARS-CoV, SARS-CoV-2, Tixagevimab, cilgavimab, immunocompromised, mRNA, patients, tixagevimab
Author NameAffiliation
Vincent C MarconiAtlanta Veterans Affairs Medical Center
Vincent C MarconiEmory University School of Medicine
Francesca CunninghamUS Department of Veterans Affairs, Center for Medication Safety
Adit A GindeUniversity of Colorado School of Medicine
  • 1 - 4

Datasets

Release 1.2